

DEC 16 2004

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449 PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/722,184
		Filing Date	November 25, 2003
		First Named Inventor	Phillips
		Art Unit	1625
		Examiner Name	Unknown
Sheet 1	3	Attorney Docket Number	03207556

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/CC/	A1	4620008	10/28/86	Brandstrom, et al.	
	A2	4628098	12/09/86	Nohara et al.	
	A3	4636499	01/13/87	Brandstrom, et al.	
	A4	4689333	08/25/87	Nohara et al.	
	A5	4725691	02/16/88	Brandstrom, et al.	
	A6	5219870	06/15/93	Kim	
	A7	5232706	08/03/93	Coll	
	A8	5244670	09/14/93	Upson, et al.	
	A9	5288506	02/22/94	Spickett, et al.	
	A10	6068859	05/30/00	Curatolo et al.	
	A11	6262085	07/17/01	Whittle et al.	
	A12	6262086	07/17/01	Whittle et al.	
	A13	6268385	07/31/01	Whittle et al.	
	A14	6489346	12/03/01	Phillips	
	A15	6328993	12/11/01	Linder et al.	
	A16	2003/0144306	07/21/03	Phillips	
	A17	6608091	08/19/03	Whittall et al.	
	A18	6608092	08/19/03	Fujishima et al.	
	A19	6608210	08/19/03	Naka et al.	
	A20	6623759	09/23/03	Heese et al.	
	A21	2003/0181457	09/25/03	Orme et al.	
	A22	2003/0199580	10/23/03	Kishi et al.	
	A23	6645988	11/11/03	Phillips	
	A24	2003/0211147	11/13/03	Cullen et al.	
	A25	6649609	11/18/03	Teuber et al.	
	A26	2003/0215527	11/20/03	Phillips	
	A27	2003/0225136	12/04/03	Whittle et al.	
	A28	6664276	12/16/03	Fujishima et al.	
	A29	6677455	01/13/04	Kronstrom et al.	
	A30	2004/0010151	01/15/04	Finkelstein et al.	
	A31	6699885	03/02/04	Phillips	
	A32	2004/0048896	03/11/04	Phillips	
/CC/	A33	2004/0058018	03/25/04	Phillips	

Examiner Signature	/Celia Chang/	Date Considered	4/26/2006
-----------------------	---------------	--------------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**BEST AVAILABLE COPY**

Substitute for form 1449/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			Application Number	10/722,184
			Filing Date	November 25, 2003
			First Named Inventor	Phillips
			Art Unit	1625
			Examiner Name	Unknown
Sheet	2	3	Attorney Docket Number	03207556

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
		Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>4</sup> (if known)				
/CC/	B1	EP 0040639	12/02/81			
	B2	EP 0670160	07/14/99			
	B3	EP 1043977	10/22/03			
	B4	EP 1375497	01/02/04			
	B5	JP 51 017268	06/01/76			
	B6	JP 59 095997	06/02/84			
	B7	JP 05 194224	08/03/93			
	B8	WO 8900566	01/26/89			
	B9	WO 9003184	04/05/90			
	B10	WO 9009175	08/23/90			
	B11	WO 9221331	12/10/92			
	B12	WO 9313138	03/21/95			
	B13	WO 95/32958	12/07/95			
	B14	WO 9936060	07/22/99			
	B15	WO 0113919	03/01/01			
	B16	WO 0151050	07/19/01			
	B17	WO 03009846	02/06/03			
	B18	WO 0001372	07/08/03			
	B19	WO 03061584	07/31/03			
	B20	WO 03063927	08/07/03			

NON PATENT LITERATURE		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/CC/	C1	"Agents for Control of Gastric Acidity and Treatment of Peptic Ulcers", Chapter 37, pp. 907-909, 1768.
	C2	"Buffered and Isotonic Solutions", <u>Physical Pharmacy</u> , Chapter 8, pp. 169-189.
	C3	ADAMS, S. P., et al., "Comments on the Report of 'association' of Omeprazole with DNA by Phillips, et al.", <u>Mutagenesis</u> , Vol. 7, No. 5, pp. 395-396 (September 1992).
	C4	AIHARA, Takeshi et al., "Pharmacological Control of Gastric Acid Secretion for the Treatment of Acid-related Peptic Disease: Past, Present, and Future", <u>Pharmacology &amp; Therapeutics</u> 98, pp. 109-127 (2003).
/CC/	C5	AMERICAN MEDICAL ASSOCIATION, Division of Drugs and Toxicology Department of Drugs, "Drug Evaluations Annual 1992", Vol. 2 (1992).

Examiner Signature	/Celia Chang/	Date Considered	4/26/2006
-----------------------	---------------	--------------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

Application Number	10/722,184
Filing Date	November 25, 2003
First Named Inventor	Phillips
Art Unit	1625
Examiner Name	Unknown
Attorney Docket Number	03207556

Attorney Docket Number	03207556
------------------------	----------

/GC/

C6	HUBER, R., "Pharmacokinetics of Pantoprazole in Man", <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 34, No. 5, pp. 185-194 (1996)
----	-------------------------------------------------------------------------------------------------------------------------------------------------------------------

C7	LEY, B. et al., "Bioavailability of a Crushed Pantoprazole Tablet after Buffering with Sodium Hydrogencarbonate or Magaldrate Relative to the Intact Enteric Coated Pantoprazole Tablet", <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , Vol. 23, pp. 41-45 (2001).
----	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

C8	"Supplemental Information Disclosure Statement" as filed with U.S. Patent and Trademark Office on December 21, 2001 for U.S. Application No. 09/481,207 (U.S. Patent 6,489,346.
----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

C9	MARTIN, L., et al., "Stress Ulcers and Organ Failure in Intubated Patients in Surgical Intensive Care Units", Ann. Surg., Vol. 215, No. 4, (April 1992).
----	----------------------------------------------------------------------------------------------------------------------------------------------------------

C10	PHILLIPS, J., et al., "A Randomized, Pharmacokinetic and Pharmacodynamic, Cross-over Study of Duodenal of Jejunal Administration Compared to Nasogastric Administration of Omeprazole Suspension in Patients at Risk for Stress Ulcers", <u>The American Journal of Gastroenterology</u> , Vol. 96, No. 2 (2001)
-----	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

/CC/

C11	TABATA, T. et al., "Stabilization of a New Antiulcer Drug (Lansoprazole) in the Solid Dosage Forms", <u>Drug Development and Industrial Pharmacy</u> , Vol. 18, pp. 1437-1447 (1992).
-----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date Considered 4/26/2006

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-768-9199) and select option 2.